Institution
VU University Amsterdam
Education•Amsterdam, Noord-Holland, Netherlands•
About: VU University Amsterdam is a education organization based out in Amsterdam, Noord-Holland, Netherlands. It is known for research contribution in the topics: Population & Poison control. The organization has 33856 authors who have published 75643 publications receiving 3414264 citations.
Papers published on a yearly basis
Papers
More filters
••
University of Leicester1, Centre national de la recherche scientifique2, Earth System Research Laboratory3, Cooperative Institute for Research in Environmental Sciences4, Norwegian Institute for Air Research5, United Kingdom Department for Environment, Food and Rural Affairs6, Japan Agency for Marine-Earth Science and Technology7, International Institute for Applied Systems Analysis8, Danish Meteorological Institute9, Paul Scherrer Institute10, ETH Zurich11, University of California, Irvine12, University of Leeds13, Aristotle University of Thessaloniki14, École Polytechnique Fédérale de Lausanne15, Geophysical Fluid Dynamics Laboratory16, National Center for Atmospheric Research17, Stockholm University18, Swiss Federal Laboratories for Materials Science and Technology19, Forschungszentrum Jülich20, University of Oslo21, Max Planck Society22, University of Helsinki23, Joseph Fourier University24, Blaise Pascal University25, University of York26, University of Toulouse27, University of Urbino28, University of Manchester29, National University of Ireland, Galway30, University of Edinburgh31, Heidelberg University32, University of East Anglia33, Weizmann Institute of Science34, Norwegian Meteorological Institute35, Chalmers University of Technology36, Energy Research Centre of the Netherlands37, University of Stuttgart38, VU University Amsterdam39
TL;DR: A review of the state of scientific understanding in relation to global and regional air quality is outlined in this article, in terms of emissions, processing and transport of trace gases and aerosols.
760 citations
••
TL;DR: In patients with AML who are older than 60 years of age, escalation of the dose of daunorubicin to twice the conventional dose, with the entire dose administered in the first induction cycle, effects a more rapid response and a higher response rate than does the conventional doses, without additional toxic effects.
Abstract: BACKGROUND: A complete remission is essential for prolonging survival in patients with acute myeloid leukemia (AML). Daunorubicin is a cornerstone of the induction regimen, but the optimal dose is unknown. In older patients, it is usual to give daunorubicin at a dose of 45 to 50 mg per square meter of body-surface area. METHODS: Patients in whom AML or high-risk refractory anemia had been newly diagnosed and who were 60 to 83 years of age (median, 67) were randomly assigned to receive cytarabine, at a dose of 200 mg per square meter by continuous infusion for 7 days, plus daunorubicin for 3 days, either at the conventional dose of 45 mg per square meter (411 patients) or at an escalated dose of 90 mg per square meter (402 patients); this treatment was followed by a second cycle of cytarabine at a dose of 1000 mg per square meter for 6 days. The primary end point was event-free survival. RESULTS: The complete remission rates were 64% in the group that received the escalated dose of daunorubicin and 54% in the group that received the conventional dose (P=0.002); the rates of remission after the first cycle of induction treatment were 52% and 35%, respectively (P<0.001). There was no significant difference between the two groups in the incidence of hematologic toxic effects, 30-day mortality (11% and 12% in the two groups, respectively), or the incidence of moderate, severe, or life-threatening adverse events (P=0.08). Survival end points in the two groups did not differ significantly overall, but patients in the escalated-treatment group who were 60 to 65 years of age, as compared with the patients in the same age group who received the conventional dose, had higher rates of complete remission (73% vs. 51%), event-free survival (29% vs. 14%), and overall survival (38% vs. 23%). CONCLUSIONS: In patients with AML who are older than 60 years of age, escalation of the dose of daunorubicin to twice the conventional dose, with the entire dose administered in the first induction cycle, effects a more rapid response and a higher response rate than does the conventional dose, without additional toxic effects. (Current Controlled Trials number, ISRCTN77039377; and Netherlands National Trial Register number, NTR212.)
759 citations
••
University of Manchester1, Imperial College London2, Central Manchester University Hospitals NHS Foundation Trust3, Harvard University4, Ford Motor Company5, King's College London6, University Medical Center Groningen7, University of Cambridge8, University of Oxford9, The Royal Marsden NHS Foundation Trust10, University of Leeds11, University of Michigan12, European Organisation for Research and Treatment of Cancer13, Institute of Cancer Research14, University College London15, United States Military Academy16, VU University Amsterdam17, University of Wisconsin-Madison18, Maastricht University19, Institut Gustave Roussy20, Robarts Research Institute21, Memorial Sloan Kettering Cancer Center22, Newcastle University23, University of Leicester24, Mount Vernon Hospital25, Johns Hopkins University26, Hofstra University27, University of Birmingham28, University of Antwerp29, Duke University30, Brighton and Sussex Medical School31, University of Sheffield32, University of Texas at Austin33
TL;DR: Experts assembled to review, debate and summarize the challenges of IB validation and qualification produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical validation, biological/clinical validation and assessment of cost-effectiveness.
Abstract: Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET and ultrasonography biomarkers are used extensively in cancer research and drug development. New IBs need to be established either as useful tools for testing research hypotheses in clinical trials and research studies, or as clinical decision-making tools for use in healthcare, by crossing 'translational gaps' through validation and qualification. Important differences exist between IBs and biospecimen-derived biomarkers and, therefore, the development of IBs requires a tailored 'roadmap'. Recognizing this need, Cancer Research UK (CRUK) and the European Organisation for Research and Treatment of Cancer (EORTC) assembled experts to review, debate and summarize the challenges of IB validation and qualification. This consensus group has produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical (assay) validation, biological/clinical validation and assessment of cost-effectiveness; the need for IB standardization and accreditation systems; the need to continually revisit IB precision; an alternative framework for biological/clinical validation of IBs; and the essential requirements for multicentre studies to qualify IBs for clinical use.
758 citations
••
TL;DR: A unified and consistent framework for introducing time-varying parameters in a wide class of non-linear models, referred to as Generalized Autoregressive Score (GAS) models, which encompasses other well-known models such as the generalized autoregressive conditional heteroskedasticity.
Abstract: We propose a class of observation driven time series models referred to as Generalized Autoregressive Score (GAS) models. The mechanism to update the parameters over time is the scaled score of the likelihood function. This new approach provides a unified and consistent framework for introducing time-varying parameters in a wide class of non-linear models. The GAS model encompasses other well-known models such as the generalized autoregressive conditional heteroskedasticity, the autoregressive conditional duration, the autoregressive conditional intensity, and Poisson count models with time-varying mean. In addition, our approach can lead to new formulations of observation driven models. We illustrate our framework by introducing new model specifications for time-varying copula functions and for multivariate point processes with time-varying parameters. We study the models in detail and provide simulation and empirical evidence.
758 citations
••
Vienna University of Technology1, Centre national de la recherche scientifique2, European Centre for Medium-Range Weather Forecasts3, National Research Council4, ETH Zurich5, Finnish Meteorological Institute6, Nanjing University of Information Science and Technology7, VU University Amsterdam8, Ghent University9, University College Cork10, Starlab11
TL;DR: The European Space Agency (ESA) released the first multi-decadal, global satellite-observed soil moisture (SM) dataset as part of its Climate Change Initiative (CCI) program.
756 citations
Authors
Showing all 34285 results
Name | H-index | Papers | Citations |
---|---|---|---|
Albert Hofman | 267 | 2530 | 321405 |
Raymond J. Dolan | 196 | 919 | 138540 |
Cornelia M. van Duijn | 183 | 1030 | 146009 |
Paul M. Thompson | 183 | 2271 | 146736 |
David A. Weitz | 178 | 1038 | 114182 |
Dorret I. Boomsma | 176 | 1507 | 136353 |
Brenda W.J.H. Penninx | 170 | 1139 | 119082 |
Kaj Blennow | 160 | 1845 | 116237 |
Vilmundur Gudnason | 159 | 837 | 123802 |
Lex M. Bouter | 158 | 767 | 103034 |
Wolfgang Wagner | 156 | 2342 | 123391 |
Frederik Barkhof | 154 | 1449 | 104982 |
Harry Campbell | 150 | 897 | 115457 |
Walter Paulus | 149 | 809 | 86252 |
James F. Wilson | 146 | 677 | 101883 |